Newamsterdam Pharma Company N.v.
A biotech company developing a once-daily oral pill to lower "bad" LDL cholesterol in people at risk of heart disease. Its lead drug, obicetrapib, met its goals in three late-stage trials and is also being studied for Alzheimer's disease. Founded in 2019 by Dutch lipidologist John Kastelein and investor Forbion, the company's name bridges its Dutch roots and US ambitions. The drug itself was famously rescued from the scrap heap after drug giant Amgen shelved it, reviving a treatment rivals had abandoned.
Bought 1.9K
Granted 831.0K · Sold 761.6K
Granted 325.5K · Sold 351.5K
Granted 125.5K · Sold 105.1K
Granted 3.4K · Sold 72.8K
Granted 575.1K · Sold 565.7K
Granted 3.4K
Granted 3.4K
Granted 3.4K
Granted 3.4K
Granted 3.4K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Topper James NDirector · 2 transactions | 0% | 6.83M | — | 1.9K | — |
| Davidson Michael H.Chief Executive Officer, Director · 14 transactions | — | 903.6K | 831.0K | — | 761.6K |
| Kastelein Johannes Jacob PieterChief Scientific Officer, Director · 10 transactions | +30.3% | 424.3K | 325.5K | — | 351.5K |
| Somaiya Mayur IanChief Financial Officer · 9 transactions | +85.6% | 98.2K | 125.5K | — | 105.1K |
| Lange Louis GDirector · 5 transactions | -41.4% | 38.9K | 3.4K | — | 72.8K |
| Kooij Louise FrederikaChief Accounting Officer · 31 transactions | +64.4% | 24.7K | 575.1K | — | 565.7K |
| Gulfo Adele M.Director · 1 transaction | +31.3% | 14.3K | 3.4K | — | — |
| Lewis WilliamDirector · 1 transaction | +48.9% | 10.4K | 3.4K | — | — |
| McKenna Mark C.Director · 1 transaction | +48.9% | 10.4K | 3.4K | — | — |
| Smither John WDirector · 1 transaction | +48.9% | 10.4K | 3.4K | — | — |
| van der Kamp Hilde JohannaDirector · 1 transaction | +48.9% | 10.4K | 3.4K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last year: -1.85M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.